CK Life Sciences Int’l., (Holdings) Inc. (CK Life Sciences) has dispatched its annual general meeting (AGM) circular, outlining key resolutions for shareholder approval on 21 May 2026.

Key agenda items

1. Director elections • Four directors—Dr Toh Kean Meng (Executive), Peter Peace Tulloch (Non-executive), and independent non-executives Kwan Kai Cheong and Donald Jeffrey Roberts—will stand for re-election. • All four have confirmed eligibility and, where applicable, independence under Hong Kong Listing Rules.

2. Director and committee remuneration • Annual base fee: HK$100,000 per director. • Committee fees per member per year: Audit HK$140,000; Remuneration HK$35,000; Nomination HK$35,000; Sustainability HK$35,000. • New rates apply to financial years commencing 1 January 2026 and remain until varied by shareholders.

3. General mandates • Share issue mandate: authority to allot and dispose of new shares up to 10% of issued share capital, with the issue price capped at a 10% discount to the benchmarked price. • Share buy-back mandate: authority to repurchase up to 10% of issued shares; repurchased shares may be cancelled or held as treasury stock in line with Listing Rules.

AGM logistics

• Date & time: Thursday, 21 May 2026, 9:00 a.m. (Hong Kong time). • Format: hybrid meeting at Harbour Grand Kowloon (Hung Hom) and via Lumi online platform. • Record date: Thursday, 21 May 2026; share transfer deadline 4:30 p.m., Friday, 15 May 2026. • Proxy deadline: 9:00 a.m., Tuesday, 19 May 2026.

Should black-rain or typhoon signal No. 8 (or “extreme conditions”) be in force at 7:00 a.m. on 21 May, the AGM will be deferred to 27 May 2026 at the same time and venue.